Literature DB >> 2022187

Structure-function analysis of interleukin-5 utilizing mouse/human chimeric molecules.

A N McKenzie1, S C Barry, M Strath, C J Sanderson.   

Abstract

Interleukin-5 (IL5) is a T cell derived glycoprotein that stimulates eosinophil production and activation. In the mouse, but apparently not in the human, it is active on B cells. The murine and human IL5 polypeptides exhibit 70% sequence similarity and yet display distinct species-specific activity. Whilst mouse and human IL5 are equally active in human cell assays, human IL5 is 100-fold less active than murine IL5 in mouse cell assays. Two restriction sites were utilized to divide the human and mouse sequences into three fragments. Hybrid molecules consisting of all combinations of these fragments were constructed and expressed. In the human cell assays [using bone marrow or the erythroleukaemic cell line (TF-1)] all the hybrid proteins generated activity comparable to that of the human and mouse IL5. This implies that replacing different domains does not result in detrimental effects to the tertiary structure of the molecule. In the mouse cell assays [using bone marrow or the pro-B cell line (B13)] the hybrids clearly identified the importance of residues in the C terminus for biological activity. The changing of only eight residues in this region of human IL5, to those of mouse IL5, resulted in the hybrid producing biological activity comparable to mouse IL5. In addition, competition binding assays showed that this region probably interacts with the receptor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2022187      PMCID: PMC452773          DOI: 10.1002/j.1460-2075.1991.tb08060.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  41 in total

1.  Identification of critical regions in mouse granulocyte-macrophage colony-stimulating factor by scanning-deletion analysis.

Authors:  A B Shanafelt; R A Kastelein
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

2.  Dimerization of B-type platelet-derived growth factor receptors occurs after ligand binding and is closely associated with receptor kinase activation.

Authors:  C H Heldin; A Ernlund; C Rorsman; L Rönnstrand
Journal:  J Biol Chem       Date:  1989-05-25       Impact factor: 5.157

3.  Characterization of high-affinity receptors for interleukin 5 on interleukin 5-dependent cell lines.

Authors:  S Mita; A Tominaga; Y Hitoshi; K Sakamoto; T Honjo; M Akagi; Y Kikuchi; N Yamaguchi; K Takatsu
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

4.  Reciprocal inhibition of binding between interleukin 3 and granulocyte-macrophage colony-stimulating factor to human eosinophils.

Authors:  A F Lopez; J M Eglinton; D Gillis; L S Park; S Clark; M A Vadas
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

5.  Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin.

Authors:  T Kitamura; T Tange; T Terasawa; S Chiba; T Kuwaki; K Miyagawa; Y F Piao; K Miyazono; A Urabe; F Takaku
Journal:  J Cell Physiol       Date:  1989-08       Impact factor: 6.384

6.  Variants of human tissue-type plasminogen activator that lack specific structural domains of the heavy chain.

Authors:  M J Gething; B Adler; J A Boose; R D Gerard; E L Madison; D McGookey; R S Meidell; L M Roman; J Sambrook
Journal:  EMBO J       Date:  1988-09       Impact factor: 11.598

7.  Mouse interleukin-2 structure-function studies: substitutions in the first alpha-helix can specifically inactivate p70 receptor binding and mutations in the fifth alpha-helix can specifically inactivate p55 receptor binding.

Authors:  S M Zurawski; G Zurawski
Journal:  EMBO J       Date:  1989-09       Impact factor: 11.598

8.  Functional analysis of the ligand binding site of EGF-receptor utilizing chimeric chicken/human receptor molecules.

Authors:  I Lax; F Bellot; R Howk; A Ullrich; D Givol; J Schlessinger
Journal:  EMBO J       Date:  1989-02       Impact factor: 11.598

9.  Monoclonal antibodies reactive with the mouse interleukin 5 receptor.

Authors:  A G Rolink; F Melchers; R Palacios
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

10.  Identification of three critical regions within mouse interleukin 2 by fine structural deletion analysis.

Authors:  S M Zurawski; G Zurawski
Journal:  EMBO J       Date:  1988-04       Impact factor: 11.598

View more
  14 in total

1.  The carboxy-terminal region of human interleukin-5 is essential for maintenance of tertiary structure but not for dimerization.

Authors:  A E Proudfoot; S C Brown; P Graber; F Talabot; C Y Arod; M C Peitsch; M Banks; M McKinnon; R Solari; T N Wells
Journal:  J Protein Chem       Date:  1996-07

2.  Mutagenesis in the C-terminal region of human interleukin 5 reveals a central patch for receptor alpha chain recognition.

Authors:  T Morton; J Li; R Cook; I Chaiken
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

3.  Saturation mutagenesis of the human interleukin 6 receptor-binding site: implications for its three-dimensional structure.

Authors:  R Savino; A Lahm; M Giorgio; A Cabibbo; A Tramontano; G Ciliberto
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

4.  Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function.

Authors:  A N McKenzie; J A Culpepper; R de Waal Malefyt; F Brière; J Punnonen; G Aversa; A Sato; W Dang; B G Cocks; S Menon
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

5.  A critical cytoplasmic domain of the interleukin-5 (IL-5) receptor alpha chain and its function in IL-5-mediated growth signal transduction.

Authors:  S Takaki; H Kanazawa; M Shiiba; K Takatsu
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

6.  Identification of receptor-binding domains on human interleukin 5 and design of an interleukin 5-derived receptor antagonist.

Authors:  J Tavernier; T Tuypens; A Verhee; G Plaetinck; R Devos; J Van der Heyden; Y Guisez; C Oefner
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

7.  A human interleukin 3 analog with increased biological and binding activities.

Authors:  A F Lopez; M F Shannon; S Barry; J A Phillips; B Cambareri; M Dottore; P Simmons; M A Vadas
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

8.  The amino-terminal helix of GM-CSF and IL-5 governs high affinity binding to their receptors.

Authors:  A B Shanafelt; A Miyajima; T Kitamura; R A Kastelein
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

9.  Detailed analysis of the IL-5-IL-5R alpha interaction: characterization of crucial residues on the ligand and the receptor.

Authors:  S Cornelis; G Plaetinck; R Devos; J Van der Heyden; J Tavernier; C J Sanderson; Y Guisez; W Fiers
Journal:  EMBO J       Date:  1995-07-17       Impact factor: 11.598

10.  Inter-species chimeras of leukaemia inhibitory factor define a major human receptor-binding determinant.

Authors:  C M Owczarek; M J Layton; D Metcalf; P Lock; T A Willson; N M Gough; N A Nicola
Journal:  EMBO J       Date:  1993-09       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.